EIKN (NASDAQ:EIKN) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of EIKN (NASDAQ:EIKN) in a report issued on Monday, MarketBeat.com reports. The firm issued an overweight rating on the stock.

Other research analysts also recently issued research reports about the company. Bank of America initiated coverage on EIKN in a report on Monday. They set a “buy” rating and a $34.00 price target on the stock. Wall Street Zen upgraded EIKN to a “hold” rating in a research report on Monday, February 16th. JPMorgan Chase & Co. began coverage on EIKN in a research note on Monday. They set an “overweight” rating and a $29.00 target price on the stock. Mizuho began coverage on shares of EIKN in a research report on Monday. They issued an “outperform” rating and a $26.00 price target for the company. Finally, Wedbush began coverage on shares of EIKN in a report on Thursday, February 26th. They set an “underperform” rating and a $7.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.60.

EIKN Stock Performance

NASDAQ EIKN opened at $15.16 on Monday. EIKN has a twelve month low of $13.28 and a twelve month high of $17.40.

About EIKN

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.